Jessica Ritsick, Yifan Wang, Ph.D. Our FDA: Drug & Device Team analyzes the Food and Drug Administration’s new guidance on Bayesian approaches to innovative drug trials, providing greater clarity on ...
In the 20th-century statistics wars, Bayesians were underdogs. Now their methods may help speed treatments to market.
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
Pediatric clinical trials commonly experience recruitment challenges including limited number of patients and investigators, inclusion/exclusion criteria that further reduce the patient pool, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results